Background: Incretin and Glucagon Receptor Systems
The incretin axis encompasses glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), both secreted from enteroendocrine cells (L-cells and K-cells, respectively) in response to nutrient ingestion. GLP-1 and GIP act through their cognate receptors — GLP-1R and GIPR — which are class B1 GPCRs (secretin receptor family) coupling primarily to Gαs and activating adenylyl cyclase to elevate intracellular cAMP. GLP-1R is expressed in pancreatic β-cells, brain (hypothalamus, brainstem), heart, kidney, and lung; GIPR expression is enriched in pancreatic β-cells, adipocytes, and brain. Glucagon receptor (GCGR) is a third class B1 GPCR predominantly expressed in hepatocytes, where it drives glycogenolysis and gluconeogenesis via Gαs-PKA signaling. All research described is for scientific laboratory purposes only. Not for human use.
Retatrutide: Molecular Identity and Design
Retatrutide (developmental code LY3437943; CAS: 2381002-32-2) is a 36-amino acid synthetic peptide developed by Eli Lilly and Company as a triple agonist of GLP-1R, GIPR, and GCGR. Its sequence was engineered through iterative analog synthesis of glucagon-based scaffolds with strategic amino acid substitutions to achieve activity at all three receptors with differentiated potency. The peptide is C-terminally amidated and incorporates a C18 fatty diacid moiety conjugated via a γGlu-miniPEG linker at Lys at position 10, enabling albumin binding and extending half-life to approximately 6 days in human research subjects (Jastreboff et al., 2023, N Engl J Med).
The backbone incorporates multiple modifications typical of peptide drug optimization: Aib (α-aminoisobutyric acid) substitutions at positions known to confer α-helical stability and DPP-IV resistance; His at position 1 (critical for GCGR activation); Glu at position 3 (critical for GLP-1R selectivity over GCGR); and Ser→Aib at position 2 to prevent DPP-IV cleavage, which otherwise rapidly inactivates native GLP-1 (t½ of ~2 minutes for GLP-1(7-36)NH₂).
Receptor Binding Kinetics and Potency Profiling
In radioligand competition binding assays using membranes from CHO cells stably expressing each receptor, retatrutide demonstrated:
- GLP-1R: IC₅₀ ≈ 0.4 nM (vs. native GLP-1 IC₅₀ ≈ 0.3 nM)
- GIPR: IC₅₀ ≈ 1.9 nM (vs. native GIP IC₅₀ ≈ 0.5 nM)
- GCGR: IC₅₀ ≈ 0.6 nM (vs. native glucagon IC₅₀ ≈ 0.4 nM)
(Data from Urva et al., 2022, Diabetes Obes Metab, and internal Lilly disclosures.) The balanced triple agonism distinguishes retatrutide from approved dual agonists such as tirzepatide (GLP-1R/GIPR only) and positions GCGR activity as an additional lever for modulating hepatic glucose output and energy expenditure research endpoints.
Gαs-cAMP Signaling and β-Arrestin Recruitment
Upon retatrutide binding, each receptor undergoes conformational change in transmembrane helices 5 and 6, displacing the intracellular Gαs α5 helix engagement site and facilitating Gαs coupling. GTP loading of Gαs dissociates the heterotrimeric complex, and Gαs·GTP activates adenylyl cyclase isoforms (primarily AC5/6 in β-cells and AC6/7 in adipocytes) to produce cAMP from ATP. cAMP activates PKA (via PRKAR1A/PRKAR2A regulatory subunit dissociation) and EPAC1/2 (exchange proteins directly activated by cAMP), leading to:
- PKA → CREB phosphorylation (Ser133) → PDX1 and FOXA2 transcription of insulin gene (INS)
- PKA → RIM2α phosphorylation → L-type Ca²⁺ channel sensitization → insulin granule exocytosis
- EPAC2 → Rap1-GTP → CDC42 activation → F-actin remodeling at secretory pole
β-arrestin recruitment — assessed by HTRF or BRET-based assays — mediates GPCR desensitization (via GRK2/3-mediated receptor phosphorylation) and initiates G protein-independent signaling through ERK1/2 and endosomal AKT pathways. Biased agonism analysis of retatrutide indicates slight Gαs preference relative to β-arrestin compared to native GLP-1, which may prolong cAMP signaling by reducing receptor internalization kinetics (Urva et al., 2022).
GCGR Pharmacology: Hepatic and Energy Expenditure Research
Glucagon receptor (GCGR) agonism in hepatocytes activates PKA-dependent phosphorylation of CREB, inducing transcription of PEPCK (PCK1), G6Pase (G6PC), and FBPase — gluconeogenic enzymes — while also activating glycogen phosphorylase (PYGL) to mobilize hepatic glycogen stores. In the context of GLP-1R/GIPR co-agonism (which drives insulin secretion), simultaneous GCGR agonism creates a complex metabolic environment that research has associated with increased hepatic fat oxidation (via PKA→HSL→ATGL lipolysis pathway) and REE (resting energy expenditure) elevation through uncoupling protein 1 (UCP1) in brown adipose tissue.
The hepatic metabolic program driven by GCGR agonism includes FGF21 (fibroblast growth factor 21) secretion: PKA phosphorylates and activates CREB-regulated transcription coactivator 2 (CRTC2), which co-activates PGC-1α and ATF4 at the FGF21 promoter, inducing FGF21 gene transcription. FGF21 acts on FGFR1c/β-Klotho complexes in white and brown adipose tissue to drive adiponectin secretion and lipolytic gene programs (Coskun et al., 2008, Endocrinology).
Phase II Clinical Research Data
The SURMOUNT-1–adjacent Phase 2 trial (NCT04881760) published in the New England Journal of Medicine (Jastreboff et al., 2023) evaluated retatrutide in adults with obesity (BMI ≥30) over 48 weeks. Key pharmacodynamic endpoints included:
- Dose-dependent reductions in body weight percentage with maximum mean reduction of −24.2% at 12 mg weekly dose at 48 weeks (vs. −2.1% placebo)
- HbA1c reductions in participants with type 2 diabetes comorbidity
- Improvements in triglycerides, LDL-cholesterol, and hepatic fat fraction by MRI-PDFF
These data represent human pharmacodynamic endpoints in clinical research context; the mechanistic interpretations are therefore more robust than preclinical data alone. Adverse event profiles were dominated by GI effects (nausea, vomiting, diarrhea) consistent with GLP-1R agonism and dose-titration-dependent onset, which is characteristic of this receptor class.
Structural Biology Insights
Cryo-EM structural analysis of GLP-1R bound to GLP-1 and Gαs (Zhang et al., 2017, Nature) and subsequent structures with dual/triple agonist scaffolds have revealed key determinants of GCGR vs. GLP-1R selectivity: the extracellular domain (ECD) binds the C-terminal α-helical portion of the peptide ligand, while the transmembrane bundle engages the N-terminal "pharmacophore" (residues 1–7). Retatrutide's Glu³ substitution enables hydrogen bonding with Lys197 and Glu125 in the GLP-1R TM bundle that is not recapitulated in GCGR (which has Ala at equivalent positions), explaining the differential potency across receptors at the molecular level.
Research Procurement Notes
Retatrutide is available as a research-grade lyophilized peptide for laboratory investigation of GLP-1R/GIPR/GCGR signaling pharmacology. View Iron All Day's retatrutide product page for full analytical documentation including HPLC chromatogram and MS confirmation.
Disclaimer: For research purposes only. Not for human consumption. All products are sold strictly for laboratory use. These statements have not been evaluated by the FDA.